Clinical trial
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in…
NCT02301624 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT02301624 |
|---|---|
| Title | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis |
| Official title | A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Refractory Generalized Myasthenia Gravis |
| Intervention type | Biological, Drug |
| Interventions | Eculizumab, Placebo |
| Enrollment | 117 |
| Start date | Nov 12, 2014 |
| Primary completion | Jan 15, 2019 |
| Completion | Jan 15, 2019 |
| First posted | Nov 26, 2014 |
| Last update posted | Feb 5, 2020 |
| Countries | Argentina, Belgium, Brazil, Canada, Czechia, Denmark, Finland, Hungary, Italy, Japan, Netherlands, South Korea and 5 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: